Eckert & Ziegler SE (CHIX:EUZD) ROCE % : 15.51% (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Eckert & Ziegler SE ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Eckert & Ziegler SE's annualized ROCE % for the quarter that ended in Sep. 2024 was 15.51%.

Eckert & Ziegler SE ROCE % Historical Data

The historical data trend for Eckert & Ziegler SE's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eckert & Ziegler SE ROCE % Chart

Eckert & Ziegler SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

15.24

13.77

18.04

14.74

13.11

Eckert & Ziegler SE Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															17.00	10.28	16.05	18.33	15.51

Eckert & Ziegler SE ROCE % Calculation

Eckert & Ziegler SE's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	46.299	/	( ( (407.456 - 56.653)	+	(439.364 - 83.685) )	/ 2 )
	=	46.299	/	( (350.803	+	355.679)	/ 2 )
	=	46.299	/	353.241
	=	13.11 %

Eckert & Ziegler SE's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	59.06	/	( ( (471.935 - 91.465)	+	(480.919 - 99.921) )	/ 2 )
	=	59.06	/	( ( 380.47	+	380.998 )	/ 2 )
	=	59.06	/	380.734
	=	15.51 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Eckert & Ziegler SE (CHIX:EUZd) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Eckert & Ziegler SE ROCE % Related Terms

Thank you for viewing the detailed overview of Eckert & Ziegler SE's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Eckert & Ziegler SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Eckert & Ziegler SE (CHIX:EUZd) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

1EUZ:Italy 0NZY:UK EUZ:Germany

Address

Robert-Rossle-Street 10, Berlin, BB, DEU, 13125

Website

https://www.ezag.com

Eckert & Ziegler SE is a provider of isotope technology for medical, scientific, and industrial use. It is predominantly engaged in the business of cancer therapy, industrial radiometry, and nuclear medical imaging. The company's segments are Medical, Isotope Products, and Other. The Isotope Products segment which generates key revenue, manufactures and distributes standards and radiation sources for medical and industrial purposes. The Medical segment provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. The Other segment comprises the items of the holding company. Geographically, the company generates a majority of its revenue from Europe and the rest from North America, Asia/Pacific, and other regions.

Eckert & Ziegler SE Headlines

No Headlines